Health technology assessment body NICE has said that Lynparza from AstraZeneca and MSD is not a cost-effective use of National Health Service …
Posted inTechnology News
Lynparza Rejection Highlights ‘Two-Tier’ Funding Problem In UK – Pink Sheet
